Mereo BioPharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 33
- Market Cap
- $738.4M
- Introduction
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
- Conditions
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 6
- Registration Number
- NCT01190475
- Locations
- 🇺🇸
Novartis Investigative Site, Anaheim, California, United States
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 27
- Registration Number
- NCT01116440
- Locations
- 🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸Center for Fertility and Women's Health, New Britain, Connecticut, United States
🇺🇸Practice Research Organization, Dallas, Texas, United States